E-drug: Table of contents for PhRMA 301 submission
-------------------------------------------------------------------------
This is PhRMA's current list of IPR trade complaints. Jamie
http://www.phrma.org/international/301.pdf
TABLE OF CONTENTS
INTRODUCTION i
PRIORITY FOREIGN COUNTRIES 1
ARGENTINA 2
PAKISTAN 5
POLAND 8
CONTINUED MONITORING (SECTION 306) 16
CHINA 17
PRIORITY WATCH LIST COUNTRIES 21
ASIA-PACIFIC 22
KOREA 23
NEW ZEALAND 26
PHILIPPINES 32
TAIWAN 34
EUROPE 38
CROATIA 39
HUNGARY 43
ITALY 48
MIDDLE EAST, AFRICA, SOUTH ASIA 50
INDIA 51
ISRAEL 55
LEBANON 58
MOROCCO 62
SOUTH AFRICA 68
TURKEY 78
WESTERN HEMISPHERE 81
ANDEAN COMMUNITY 82
PERU 85
BRAZIL 88
CANADA 92
DOMINICAN REPUBLIC 100
GUATEMALA 102
MEXICO 103
WATCH LIST
ASIA-PACIFIC 106
AUSTRALIA 107
INDONESIA 110
MALAYSIA 112
THAILAND 114
VIETNAM 116
EUROPE 119
LITHUANIA 120
ROMANIA 122
RUSSIA 127
SLOVENIA 136
MIDDLE EAST, AFRICA, SOUTH ASIA 140
EGYPT 141
SAUDI ARABIA 147
WESTERN HEMISPHERE 150
CHILE 151
CENTRAL AMERICA 153
COSTA RICA 154
EL SALVADOR 155
HONDURAS 156
NICARAGUA 156
COLOMBIA 158
PARAGUAY 160
URUGUAY 161
APPENDICES 162
APPENDIX A 163
ENFORCING DATA EXCLUSIVITY
APPENDIX B 170
THE IMPORTANCE OF PHARMACEUTICAL TRADEMARKS FOR
PATIENTS
APPENDIX C 176
THE COSTS TO RESEARCH-BASED PHARMACEUTICAL
COMPANIES OF
INADEQUATE DATA EXCLUSIVITY IN ARGENTINA33
Charles River Associates Inc.
Washington, D.C.
August 2001
APPENDIX D.190
THE COSTS TO RESEARCH-BASED PHARMACEUTICAL
COMPANIES OF
INADEQUATE INTELLECTUAL PROPERTY PROTECTION IN
ARGENTINA,
BRAZIL, INDIA, AND ISRAEL
By Richard D. Boltuck, David A. Riker, and Spencer R. Graf
Charles River Associates Inc.
Washington, D.C.
May 2001
--
James Love, Director, Consumer Project on Technology
http://www.cptech.org, mailto:james.love@cptech.org
tel. +1.202.387.8030, mobile +1.202.361.3040